Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 19 | 2024 | 455 | 5.700 |
Why?
|
| Tuberculosis | 21 | 2024 | 566 | 5.450 |
Why?
|
| Tuberculosis, Pulmonary | 9 | 2024 | 248 | 3.090 |
Why?
|
| DNA Methylation | 4 | 2024 | 979 | 1.950 |
Why?
|
| Immune Tolerance | 4 | 2024 | 148 | 1.910 |
Why?
|
| Epigenesis, Genetic | 4 | 2024 | 657 | 1.390 |
Why?
|
| Adaptive Immunity | 3 | 2021 | 89 | 1.370 |
Why?
|
| Molecular Diagnostic Techniques | 4 | 2023 | 146 | 1.240 |
Why?
|
| Sputum | 7 | 2024 | 111 | 1.200 |
Why?
|
| BCG Vaccine | 5 | 2023 | 113 | 1.200 |
Why?
|
| Feces | 3 | 2024 | 687 | 1.070 |
Why?
|
| Citric Acid Cycle | 1 | 2024 | 47 | 0.950 |
Why?
|
| HIV Infections | 9 | 2024 | 1859 | 0.910 |
Why?
|
| Lipopolysaccharides | 1 | 2024 | 289 | 0.850 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 35 | 0.830 |
Why?
|
| Fetal Blood | 1 | 2023 | 170 | 0.820 |
Why?
|
| Antitubercular Agents | 8 | 2024 | 341 | 0.820 |
Why?
|
| Interferon-gamma Release Tests | 2 | 2020 | 85 | 0.790 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2024 | 511 | 0.760 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 88 | 0.700 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 90 | 0.650 |
Why?
|
| Leukocytes | 1 | 2020 | 209 | 0.650 |
Why?
|
| Communicable Diseases | 1 | 2021 | 158 | 0.640 |
Why?
|
| Sensitivity and Specificity | 10 | 2024 | 1999 | 0.640 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 18 | 0.620 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 18 | 0.620 |
Why?
|
| Schistosomiasis | 1 | 2018 | 49 | 0.600 |
Why?
|
| Ascariasis | 1 | 2018 | 58 | 0.590 |
Why?
|
| Immunity, Innate | 2 | 2021 | 370 | 0.580 |
Why?
|
| Th1 Cells | 1 | 2018 | 147 | 0.580 |
Why?
|
| Transcriptome | 2 | 2022 | 900 | 0.570 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 469 | 0.560 |
Why?
|
| Schistosoma | 1 | 2016 | 9 | 0.540 |
Why?
|
| Immunologic Factors | 2 | 2021 | 172 | 0.520 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 149 | 0.500 |
Why?
|
| Humans | 45 | 2024 | 121045 | 0.480 |
Why?
|
| Population Surveillance | 2 | 2022 | 364 | 0.480 |
Why?
|
| Macrophages | 1 | 2016 | 613 | 0.400 |
Why?
|
| Signal Transduction | 2 | 2021 | 4498 | 0.380 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2539 | 0.380 |
Why?
|
| Immunologic Memory | 2 | 2021 | 175 | 0.340 |
Why?
|
| Child | 15 | 2024 | 23950 | 0.300 |
Why?
|
| Animals | 9 | 2024 | 33472 | 0.280 |
Why?
|
| Interleukin-4 | 2 | 2018 | 140 | 0.280 |
Why?
|
| South Africa | 2 | 2023 | 98 | 0.270 |
Why?
|
| Cytokines | 3 | 2022 | 1258 | 0.260 |
Why?
|
| Inflammation | 2 | 2022 | 1396 | 0.250 |
Why?
|
| Succinic Acid | 1 | 2024 | 14 | 0.240 |
Why?
|
| Succinates | 1 | 2024 | 20 | 0.240 |
Why?
|
| Interferon-gamma | 2 | 2018 | 506 | 0.240 |
Why?
|
| Biomarkers | 2 | 2024 | 2919 | 0.240 |
Why?
|
| Everolimus | 1 | 2024 | 47 | 0.240 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 478 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 358 | 0.230 |
Why?
|
| Child, Preschool | 7 | 2023 | 13708 | 0.220 |
Why?
|
| Adult | 14 | 2024 | 28363 | 0.220 |
Why?
|
| Ultraviolet Therapy | 1 | 2022 | 1 | 0.210 |
Why?
|
| Immunity | 1 | 2023 | 182 | 0.210 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 23 | 0.200 |
Why?
|
| Adolescent | 9 | 2024 | 18730 | 0.200 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.200 |
Why?
|
| Guinea Pigs | 1 | 2022 | 160 | 0.200 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 298 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 43 | 0.200 |
Why?
|
| Young Adult | 5 | 2024 | 8627 | 0.200 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 59 | 0.190 |
Why?
|
| Cryptococcus | 1 | 2021 | 3 | 0.190 |
Why?
|
| Herpesvirus 8, Human | 1 | 2021 | 49 | 0.190 |
Why?
|
| Vaccination | 2 | 2023 | 881 | 0.190 |
Why?
|
| Systems Biology | 1 | 2021 | 61 | 0.190 |
Why?
|
| Allergy and Immunology | 1 | 2021 | 24 | 0.180 |
Why?
|
| Cryptococcosis | 1 | 2021 | 42 | 0.180 |
Why?
|
| Kava | 1 | 2020 | 7 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 68 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 862 | 0.180 |
Why?
|
| Cellular Senescence | 1 | 2022 | 156 | 0.180 |
Why?
|
| History, 19th Century | 1 | 2021 | 115 | 0.180 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 120 | 0.180 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2021 | 261 | 0.180 |
Why?
|
| Eosinophilia | 1 | 2021 | 101 | 0.180 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 119 | 0.180 |
Why?
|
| Herpesviridae Infections | 1 | 2021 | 144 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 39 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 304 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 234 | 0.170 |
Why?
|
| Diarrhea | 1 | 2021 | 313 | 0.170 |
Why?
|
| Transcription Factors | 2 | 2021 | 2586 | 0.170 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 220 | 0.170 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.170 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2021 | 143 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 340 | 0.170 |
Why?
|
| History, 20th Century | 1 | 2021 | 370 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 238 | 0.160 |
Why?
|
| RNA | 1 | 2022 | 577 | 0.160 |
Why?
|
| Health Personnel | 1 | 2023 | 494 | 0.160 |
Why?
|
| Immunization | 1 | 2020 | 293 | 0.160 |
Why?
|
| Gene Expression | 1 | 2023 | 1579 | 0.160 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 57 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 59 | 0.150 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 89 | 0.150 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 34 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2021 | 421 | 0.150 |
Why?
|
| Mycobacterium chelonae | 1 | 2017 | 6 | 0.150 |
Why?
|
| Prospective Studies | 6 | 2024 | 5854 | 0.150 |
Why?
|
| Viral Vaccines | 1 | 2020 | 262 | 0.150 |
Why?
|
| Wound Healing | 1 | 2021 | 449 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2020 | 307 | 0.150 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2017 | 59 | 0.140 |
Why?
|
| Helminths | 1 | 2017 | 42 | 0.140 |
Why?
|
| Age Factors | 1 | 2023 | 2760 | 0.140 |
Why?
|
| Tanzania | 3 | 2024 | 66 | 0.140 |
Why?
|
| Calibration | 1 | 2016 | 82 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3209 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| CD56 Antigen | 1 | 2016 | 27 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2021 | 653 | 0.130 |
Why?
|
| Phagosomes | 1 | 2016 | 34 | 0.130 |
Why?
|
| Hookworm Infections | 1 | 2017 | 119 | 0.130 |
Why?
|
| CD3 Complex | 1 | 2016 | 85 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 240 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 172 | 0.130 |
Why?
|
| Coinfection | 1 | 2017 | 168 | 0.130 |
Why?
|
| Immunophenotyping | 1 | 2016 | 333 | 0.120 |
Why?
|
| Male | 11 | 2024 | 58908 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2021 | 4577 | 0.120 |
Why?
|
| Age of Onset | 1 | 2016 | 563 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 569 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 172 | 0.120 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 327 | 0.120 |
Why?
|
| Female | 11 | 2024 | 63993 | 0.120 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 83 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 355 | 0.120 |
Why?
|
| Skin | 1 | 2017 | 498 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.120 |
Why?
|
| Mozambique | 2 | 2024 | 17 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 231 | 0.120 |
Why?
|
| Risk Factors | 2 | 2020 | 9603 | 0.110 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 306 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2016 | 814 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 397 | 0.110 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1651 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2787 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1092 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3068 | 0.100 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 60 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2055 | 0.090 |
Why?
|
| Uganda | 2 | 2024 | 66 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2297 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1677 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4255 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 25263 | 0.080 |
Why?
|
| Mice | 1 | 2024 | 17432 | 0.070 |
Why?
|
| Prognosis | 1 | 2016 | 4472 | 0.070 |
Why?
|
| Aged | 2 | 2023 | 18399 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 5975 | 0.070 |
Why?
|
| Geriatric Psychiatry | 1 | 2006 | 10 | 0.070 |
Why?
|
| Foreign Medical Graduates | 1 | 2006 | 11 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2370 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 89 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 259 | 0.050 |
Why?
|
| Infant | 4 | 2021 | 12201 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 61 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 44 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2006 | 450 | 0.050 |
Why?
|
| Phototherapy | 1 | 2022 | 35 | 0.050 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 43 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 179 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 135 | 0.050 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2022 | 64 | 0.050 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 13 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 11680 | 0.050 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 20 | 0.050 |
Why?
|
| Isoniazid | 1 | 2021 | 69 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2020 | 106 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 249 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2021 | 178 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 158 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 138 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 306 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1075 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2006 | 747 | 0.040 |
Why?
|
| United States | 3 | 2022 | 10332 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1284 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 358 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 265 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2021 | 262 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 76 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 1116 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 390 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1139 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2017 | 52 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 231 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1606 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 113 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 724 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 268 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1870 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2006 | 1152 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 654 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 236 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 296 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1238 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1473 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1461 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1923 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2023 | 15563 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2006 | 163 | 0.020 |
Why?
|
| Data Collection | 1 | 2006 | 378 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 7976 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2006 | 966 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 3596 | 0.010 |
Why?
|